Ambio Pharmaceuticals is the parent company of AmbioPharm, Inc. and Ambio, Inc.
AmbioPharm, a global peptide CDMO, was founded in 2005 and is headquartered in North Augusta, South Carolina, USA specializing in developing highly efficient manufacturing processes for peptide-based Active Pharmaceutical Ingredients (APIs) at very small to very large scales. In our manufacturing facilities in South Carolina, USA and Shanghai, China, we manufacture New Chemical Entities (NCEs) and generic peptide APIs under cGMP for clients worldwide. Both facilities have been inspected multiple times by the FDA with excellent outcomes.
Ambio is a drug development company with a rich and growing pipeline of proprietary drug development programs for bioequivalent and biosimilar versions of the world’s best-selling peptide drugs.
AmbioPharm, a global peptide CDMO, was founded in 2005 and is headquartered in North Augusta, South Carolina, USA specializing in developing highly efficient manufacturing processes for peptide-based Active Pharmaceutical Ingredients (APIs) at very small to very large scales. In our manufacturing facilities in South Carolina, USA and Shanghai, China, we manufacture New Chemical Entities (NCEs) and generic peptide APIs under cGMP for clients worldwide. Both facilities have been inspected multiple times by the FDA with excellent outcomes.
Ambio is a drug development company with a rich and growing pipeline of proprietary drug development programs for bioequivalent and biosimilar versions of the world’s best-selling peptide drugs.
Location: United States, South Carolina, North Augusta
Employees: 501-1000
Phone: +1 803-442-7590
Founded date: 2005
Investors 2
| Date | Name | Website |
| - | MVM Partne... | mvm.com |
| - | The Carlyl... | carlyle.co... |
Mentions in press and media 2
| Date | Title | Description |
| 15.09.2026 | CordenPharma Appoints Dr. Jean-Luc Herbeaux as Chief Executive Officer to Lead Next Phase of Growth | Dr. Jean-Luc Herbeaux appointed Chief Executive Officer of CordenPharma, effective 1 October 2026 Dr. Michael Quirmbach to transition from President & CEO to Board Member and Senior Advisor, remaining actively involved with CordenPharma... |
| 27.05.2026 | CordenPharma Acquires AmbioPharm to Expand Global Peptide API Capacity | Acquisition strengthens U.S. peptide manufacturing capabilities and broadens global expertise in complex peptide APIs CordenPharma has entered into an agreement to acquire AmbioPharm, a U.S.-headquartered peptide CDMO with facilities in Nor... |